Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Dividends Paid - CommonExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ani Pharmaceuticals (ANIP) Share-based Compensation (2016 - 2025)

Historic Share-based Compensation for Ani Pharmaceuticals (ANIP) over the last 17 years, with Q3 2025 value amounting to $9.7 million.

  • Ani Pharmaceuticals' Share-based Compensation rose 2947.23% to $9.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $35.2 million, marking a year-over-year increase of 2622.56%. This contributed to the annual value of $29.3 million for FY2024, which is 4208.79% up from last year.
  • As of Q3 2025, Ani Pharmaceuticals' Share-based Compensation stood at $9.7 million, which was up 2947.23% from $9.6 million recorded in Q2 2025.
  • In the past 5 years, Ani Pharmaceuticals' Share-based Compensation ranged from a high of $9.7 million in Q3 2025 and a low of $1.9 million during Q1 2021
  • In the last 5 years, Ani Pharmaceuticals' Share-based Compensation had a median value of $5.2 million in 2023 and averaged $5.4 million.
  • Per our database at Business Quant, Ani Pharmaceuticals' Share-based Compensation plummeted by 5041.84% in 2021 and then surged by 7319.42% in 2022.
  • Over the past 5 years, Ani Pharmaceuticals' Share-based Compensation (Quarter) stood at $3.0 million in 2021, then grew by 25.91% to $3.7 million in 2022, then skyrocketed by 50.41% to $5.6 million in 2023, then grew by 25.62% to $7.1 million in 2024, then skyrocketed by 37.25% to $9.7 million in 2025.
  • Its Share-based Compensation was $9.7 million in Q3 2025, compared to $9.6 million in Q2 2025 and $8.9 million in Q1 2025.